Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Whitehawk Therapeutics (WHWK) over the last 5 years, with Jun 2025 value amounting to $1,000.

  • Whitehawk Therapeutics' Capital Expenditures fell 99.82% to $1,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $926,000, marking a year-over-year decrease of 71.01%. This contributed to the annual value of $1.7 million for FY2024, which is 58.36% down from last year.
  • Whitehawk Therapeutics' Capital Expenditures amounted to $1,000 in Q2 2025, which was down 99.82% from $551,000 recorded in Q1 2025.
  • Whitehawk Therapeutics' Capital Expenditures' 5-year high stood at $1.4 million during Q1 2023, with a 5-year trough of $1,000 in Q2 2025.
  • In the last 3 years, Whitehawk Therapeutics' Capital Expenditures had a median value of $620,000 in 2023 and averaged $617,800.
  • In the last 5 years, Whitehawk Therapeutics' Capital Expenditures spiked by 4,970.37% in 2023 and then crashed by 99.82% in 2025.
  • Whitehawk Therapeutics' Capital Expenditures (Quarterly) stood at $46,000 in 2021, then soared by 69.57% to $78,000 in 2022, then spiked by 946.15% to $816,000 in 2023, then slumped by 77.21% to $186,000 in 2024, then crashed by 99.82% to $1,000 in 2025.
  • Its last three reported values are $1,000 in Q2 2025, $551,000 for Q1 2025, and $186,000 during Q4 2024.